<DOC>
	<DOCNO>NCT01494987</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled , parallel-group , multi-center study determine effect ranolazine add glimepiride glycemic control adult type 2 diabetes mellitus ( T2DM ) inadequately control despite current treatment stable sulfonylurea metformin therapy addition diet exercise .</brief_summary>
	<brief_title>Ranolazine When Added Glimepiride Subjects With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Ranolazine</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<criteria>Written inform consent Males female , 18 75 year old , inclusive Documented history T2DM Receiving one follow sulfonylurea metformin therapy addition diet exercise least 90 day prior Screening : 1. glimepiride daily dose ≥ 2 mg ≤ 4 mg 2. glipizide , glyburide , glibenclamide ( equivalent ) daily dose ≥ 7.5 mg 3. gliclazide daily dose &gt; 160 mg ( ≥ 60 mg modify release [ MR ] formulation ) 4. metformin daily dose ≥ 1500 mg Body mass index ( BMI ) 25 kg/m2 45 kg/m2 , inclusive , Screening HbA1c 7 % 10 % , inclusive , Screening end Qualifying Period ( Day 14 ) Fasting Serum Cpeptide ≥ 0.8 ng/mL Screening Fasting serum glucose ( FSG ) ≥ 130 mg/dL ( 7.2 mmol/L ) ≤ 240 mg/dL ( 13.3 mmol/L ) Screening end Qualifying Period ( Day 14 ) : A onetime central laboratory retest FSG allow subject initial central laboratory FSG ≥ 120 mg/dL ( 6.7 mmol/L ) &lt; 130 mg/dL ( 7.2 mmol/L ) otherwise eligible determine investigator . Able willing comply study procedure course study Females childbearing potential must negative serum pregnancy test Screening must agree use highly effective contraception method Screening throughout duration Treatment Period 14 day follow last dose study drug . At least 80 % compliant dose Qualifying Period History current diagnosis type 1 diabetes mellitus History diabetic ketoacidosis , ketosisprone diabetes , hyperosmolar hyperglycemic coma History severe episode hypoglycemia ( ≥ 1 episode within 3 month prior Screening ≥ 2 episode within 6 month prior Screening ) , define hypoglycemia require 3rd party assistance actively administer carbohydrate , glucagon , resuscitative action due severe impairment consciousness behavior Clinically significant complication diabetes judgment investigator would make subject unsuitable participate study History clinically significant cardiovascular ( CV ) cerebrovascular event ( eg , myocardial infarction [ MI ] , acute coronary syndrome [ ACS ] , recent revascularization [ include coronary artery bypass graft procedure percutaneous coronary intervention ] , transient ischemic attack , ischemic stroke ) ≤ 3 month prior Screening Inadequately control unstable hypertension define systolic blood pressure ( SBP ) &gt; 160 mmHg diastolic blood pressure ( DBP ) &gt; 100 mmHg Screening Randomization Prolonged QT interval correct heart rate ( QTc ) interval &gt; 500 msec electrocardiogram ( ECG ) Screening , personal family history QTc prolongation , congenital long QT syndrome , subject receive drug prolong QTc interval , Class Ia Class III antiarrhythmic agent , erythromycin , certain antipsychotic ( eg , ziprasidone ) History bariatric surgery time past surgery &lt; 2 month Screening ; plan undergo surgery study . Subjects plan minor surgery may enrol upon approval medical monitor . Any hospitalization 14 day prior Screening plan hospitalization time study Significant weight change ( ± 5 % ) &lt; 2 month prior Screening enrollment weightloss program maintenance phase Screening . Severe renal impairment , define estimate glomerular filtration rate ( eGFR ) Modification Diet Renal Disease ( MDRD ) equation &lt; 30 mL/min/1.73 m2 Screening undergoing type dialysis Screening plan undergo type dialysis course study History liver cirrhosis ( ChildPugh Class A , B C ) Active liver disease and/or significant abnormal liver function define aspartate aminotransferase ( AST ) &gt; 3 x upper limit normal range ( ULN ) and/or alanine aminotransferase ( ALT ) &gt; 3 x ULN and/or serum total bilirubin &gt; 2.0 mg/dL History cancer ( except nonmelanomic skin cancer cervical situ ) within 5 year prior Screening History alcohol drug abuse &lt; 12 month prior Screening Any clinically significant exist medical psychiatric condition , include clinically significant laboratory abnormality , one require evaluation opinion investigator could interfere conduct study interpretation data Use antihyperglycemic agent sulfonylurea agent metformin , include limited dipeptidyl peptidase4 inhibitor ( eg , saxagliptin sitagliptin ) , glucagonlike peptidemimetics ( eg , exenatide ) , insulin &lt; 3 month prior Screening ; use thiazolidinediones ( TZDs ) ( eg , rosiglitazone pioglitazone ) &lt; 24 week prior Screening Previous history intolerance glimepiride ( singleagent therapy ) Prior treatment openlabel ranolazine , know hypersensitivity intolerance ranolazine excipients Treatment strong moderate cytochrome P ( CYP ) 3A inhibitor Pglycoprotein ( Pgp ) inhibitor within 14 day prior randomization Treatment CYP3A inducer Pgp inducer within 14 day prior randomization Treatment CYP3A4 substrates narrow therapeutic range ( eg , cyclosporine , tacrolimus , sirolimus ) within 14 day prior Randomization Treatment simvastatin dose &gt; 20 mg daily lovastatin dose &gt; 40 mg daily within 14 day prior Randomization Weight loss medication antiobesity medication ( prescription nonprescription ) &lt; 3 month prior Screening Treatment niacin &gt; 200 mg daily ; receive ≤ 200 mg daily , stable dos ≥ 3 month prior Screening Expected current treatment systemic corticosteroid ( oral injectable ) &gt; 14 day Screening end Treatment Period . Topical inhale corticosteroid formulation permit time study . If receive thyroid replacement therapy , stable dos least 6 week prior randomization Hemoglobin &lt; 12 g/dL male &lt; 11 g/dL female Screening Participation another clinical study involve investigational drug device &lt; 30 day prior Screening ; participation another clinical study involve oral antihyperglycemic agent ( OHA ) &lt; 90 day prior Screening Donation blood &lt; 2 month prior Screening plan donate blood participate study Females pregnant breastfeed Other condition ( ) , opinion investigator , would compromise safety individual , prevent compliance study protocol ( include ability comply Mixed Meal Tolerance Test [ MMTT ] ) , compromise quality clinical study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Type 2 Diabetes Mellitus</keyword>
</DOC>